Analyst Consensus ?
ConsensusHold28 ratings
Bullish1035.7%
Neutral1139.3%
Bearish725.0%
Globe Life Inc. · GL · FY2025 Q1 · Calendar Q2 2025
Globe Life Maintains Guidance Amid Health-Margin Pressure
The supplied analysis supports a cautiously constructive operating thesis: agent growth, expected premium-rate actions, and favorable life mortality supported maintained guidance, but higher health utilization, flat investment income, legal exposure, and regulatory uncertainty temper the outlook.
Reported After market closeNYSEFinancial Services
$12.82B market cap
70quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $3.24
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $1.49B
Revenue surprise
—
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-4.6%
Event window
SPY move
+0.7%
Same window
Abnormal move
-5.3%
Stock minus SPY
Volume
2.1×
Versus trailing sessions
Subsequent drift
+3.5%
Up to 20 sessions
GLSPY benchmark
Ask FN2 about GL FY2025 Q1
Transcript, numbers and history already loaded
What drove GL's -4.6% move after FY2025 Q1 earnings?What changed in GL's guidance and outlook in FY2025 Q1?Give me the bull and bear case for GL after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management maintained full-year earnings and sales guidance. The supplied analysis highlighted strong agent growth and expected rate actions, alongside modest health-margin compression, flat investment income, legal costs, and ongoing SEC and DOJ investigations.
Guidance delta
Management maintained full-year earnings and sales guidance; the supplied analysis indicates no change.
Key takeaways
- Management described Q1 net income as modestly higher and margins as in line with internal projections.
- The supplied analysis points to 2025 life-premium growth of 4–5% and health-premium growth of 7–8%, with modest health-margin compression.
- Agent-count growth supported confidence in sales guidance across divisions.
- Management expected investment income to be flat and continued share repurchases and dividends.
- Higher health-claim utilization, rate-filing timing, legal costs, and regulatory matters remain key watch items.
Management priorities
- Grow agent count across American Income, Liberty National, and Family Heritage.
- Execute premium-rate actions and monitor their effect on health margins.
- Invest in direct-to-consumer automation and underwriting technology.
- Manage the investment portfolio and reduce commercial paper.
- Continue planned share repurchases and dividend payments.
Follow GL with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$165.12Current
$90Low
$156Average
$200High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 13, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 12, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 5, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Jul 24, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 22, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 21, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 15, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 13, 2026 |
| Jefferies | Hold | Hold | Maintain | Jul 10, 2026 |
| Truist Securities | Buy | Buy | Maintain | Apr 24, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Jul 30, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Oct 15, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Dec 19, 2022 |
| Wolfe Research | Underperform | Underperform | Maintain | Jan 21, 2022 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Apr 24, 2020 |
| B of A Securities | Buy | Buy | Maintain | Jan 23, 2020 |
| UBS | Sell | Sell | Maintain | Oct 10, 2019 |
| Goldman Sachs | Sell | Neutral | Downgrade | Sep 10, 2018 |
| Barclays | Underweight | Underweight | Maintain | Aug 11, 2017 |
| Bank of America | Underperform | Neutral | Downgrade | Nov 18, 2016 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 29, 2016 |
| Citigroup | Neutral | Neutral | Maintain | Jul 7, 2016 |
| FBR Capital | Perform | Market Perform | Maintain | Feb 8, 2016 |
| PiperJaffray | Neutral | Neutral | Maintain | Jun 2, 2015 |
| Keefe Bruyette & Woods | Perform | Market Perform | Maintain | Apr 22, 2015 |
| Sterne Agee | Neutral | Neutral | Maintain | Oct 13, 2014 |
| Scotiabank | Underperform | Sector Perform | Downgrade | Nov 22, 2013 |
| RBC Capital | Underperform | Underperform | Maintain | Jun 28, 2013 |
| Janney Capital | Neutral | Buy | Downgrade | Jun 3, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $165.12. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Analyst unavailable | $197 | $165.25 | +19.3% | Oct 5, 2026 |
| Piper Sandler | Paul Newsome | $200 | $178.99 | +21.1% | Jul 15, 2026 |
| Jefferies | Analyst unavailable | $166 | $178.86 | +0.5% | Jul 10, 2026 |
| Piper Sandler | Analyst unavailable | $175 | $156.28 | +6.0% | May 26, 2026 |
| Morgan Stanley | Analyst unavailable | $181 | $155.3 | +9.6% | May 21, 2026 |
| Truist Financial | Mark Hughes | $185 | $153.55 | +12.0% | Apr 24, 2026 |
| Evercore ISI | Analyst unavailable | $157 | $144.86 | -4.9% | Feb 18, 2026 |
| Morgan Stanley | Bob Huang | $176 | $140.82 | +6.6% | Dec 15, 2025 |
| Piper Sandler | John Barnidge | $167 | $133.61 | +1.1% | Nov 21, 2025 |
| Truist Financial | Mark Hughes | $158 | $134.49 | -4.3% | Oct 24, 2025 |
| Morgan Stanley | Bob Huang | $179 | $134.91 | +8.4% | Oct 7, 2025 |
| Morgan Stanley | Analyst unavailable | $166 | $139.51 | +0.5% | Aug 5, 2025 |
| Morgan Stanley | Bob Huang | $127 | $119.38 | -23.1% | Jul 14, 2025 |
| Morgan Stanley | Analyst unavailable | $126 | $127.43 | -23.7% | Feb 28, 2025 |
| Raymond James | Wilma Burdis | $188 | $109.77 | +13.9% | Oct 15, 2024 |
| Evercore ISI | Thomas Gallagher | $95 | $104.4 | -42.5% | Sep 27, 2024 |
| Truist Financial | Mark Hughes | $90 | $90.25 | -45.5% | Jul 26, 2024 |
| CFRA | Catherine Seifert | $92 | $90.3 | -44.3% | Jul 26, 2024 |
| Piper Sandler | John Barnidge | $106 | $90.48 | -35.8% | Jul 26, 2024 |
| Morgan Stanley | Bob Huang | $65 | $81.91 | -60.6% | Jul 10, 2024 |
| Jefferies | Suneet Kamath | $90 | $81.91 | -45.5% | Jul 10, 2024 |
| Piper Sandler | John Barnidge | $110 | $82 | -33.4% | Apr 24, 2024 |
| CFRA | Catherine Seifert | $55 | $59.09 | -66.7% | Apr 12, 2024 |
| Evercore ISI | Thomas Gallagher | $75 | $49.17 | -54.6% | Apr 12, 2024 |
| Piper Sandler | John Barnidge | $86.71 | $32.8 | -47.5% | Apr 11, 2024 |
| CFRA | Catherine Seifert | $78.71 | $69.99 | -52.3% | Apr 11, 2024 |
| Evercore ISI | Thomas Gallagher | $125 | $115.99 | -24.3% | Mar 14, 2024 |
| Morgan Stanley | Analyst unavailable | $132 | $121.21 | -20.1% | Jan 10, 2023 |
| Credit Suisse | Analyst unavailable | $140 | $116.5 | -15.2% | Dec 19, 2022 |
| Morgan Stanley | Analyst unavailable | $115 | $111.6 | -30.4% | Nov 17, 2022 |
| Morgan Stanley | Analyst unavailable | $110 | $103.02 | -33.4% | Aug 17, 2022 |
| Morgan Stanley | Analyst unavailable | $109 | $97.31 | -34.0% | Jul 28, 2022 |
Track every rating change on GL the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationGlobe Life Inc. delivers diverse life insurance and supplementary health coverage, alongside annuity products, targeting households in the lower-middle to middle-income brackets throughout the United States. The company's operations are structured into four key segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments. Its offerings encompass whole life, term life, and other life protection plans; supplemental health benefits like Medicare supplements, critical illness, and accident policies; and both single-premium and flexible-premium deferred annuities. Founded in 1979 and headquartered in McKinney, Texas, the enterprise rebranded from Torchmark Corporation to Globe Life Inc. in August 2019.
Historical context
All GL earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| FDS FactSet Research Systems Inc. | FY2026 Q4 · Calendar Q3 2026 | +3.9% | +3.8% | FactSet reports record FY26 results as AI and MCP adoption accelerate |
| PUK Prudential plc | FY2026 Q2 · Calendar Q3 2026 | -40.9% | -0.5% | Prudential sustains growth and capital returns focus in H1 2026 |
| CM Canadian Imperial Bank of Commerce | FY2026 Q3 · Calendar Q3 2026 | +8.9% | -2.8% | CIBC Q3: Broad growth, resilient credit and expanded AI rollout |
| TD The Toronto-Dominion Bank | FY2026 Q3 · Calendar Q3 2026 | +13.8% | +1.4% | TD emphasizes growth investments alongside disciplined capital management |
Latest beats and misses
Who reports nextBeat on EPS
Get the GL recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-16T00:02:45.914612+00:00
- Polygon adjusted daily market bars · 2026-10-13T03:00:44.989888+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-13T03:00:44.987162+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-13. For educational purposes only; not investment advice.